BID Equity acquires Crisalix, the leading aesthetic 3D imaging platform
BID Equity Fund III announces the acquisition of Crisalix SA, a leading and well-positioned provider of 3D simulation technology for the aesthetic market, now even better positioned for future growth with a strong new partner.
Crisalix SA, headquartered in Lausanne, Switzerland, has redefined the way patients and physicians approach aesthetic treatments through innovative, cloud-based software solutions that enable patients and physicians to visualize aesthetic treatments. The platform helps medical professionals worldwide to grow by improving patient decision-making, building trust, and enhancing overall education. Crisalix is the trusted partner of top-tier surgeons, dermatologists, aesthetic clinics, and industry leaders providing an exclusive end to end solution. Crisalix serves a broad international client base. The solution combines cutting-edge technology with user-friendly functionality, setting new standards for innovation and excellence in the field. Dr. Jaime García, CEO of Crisalix, commented: BID Equity is a great partner to reach the next level of growth. Together, we plan to build the leading software group for patient-focused aesthetic medicine." BID Equity aims to build the leading software group in the field of aesthetic medicine in partnership with Crisalix. By combining Crisalix’s technological expertise with BID Equity’s financial resources and buy-and-build experience, the collaboration provides a solid foundation for further international growth and innovative product development. |
